Electra announces a major milestone with the successful validation of its EVE‑Ai™ Adaptive Controls platform, enabling ...

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

The partnership aims to deploy AI capabilities that automatically analyse X-ray and CT images to assist radiologists.

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the ...

US pharma major Bristol Myers Squibb has announced the appointment of Harald Hampel as senior vice president, worldwide head of medical affairs, Neuroscience.

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) turned out to be a conclusive failure, ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...

Just in time for the annual American Society of Clinical Oncology (ASCO) meeting in Chicago, Bristol Myers Squibb launched a campaign to highlight its progress in dual immuno-oncology (I-O) research ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

After several years of turning out solid growth, Bristol Myers Squibb knows it’s nearing a patent cliff that’ll wreak havoc later this decade. Still, the company believes a “diversified” ...

BMS Re, the reinsurance arm of independent re/insurance broker BMS Group, has appointed Tony Grippa as Chief Strategy Officer ...